Impressive, especially considering that the study was not powered to achieve statistical significance. 008 and the canine study just adds to the mounting evidence that iPPS will one day be approved for treatment for OA.
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial, page-20
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.5¢ | $86.19K | 286.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70151 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18600 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |